ConductScience.org, home

ConductScience Library

OpenNo account needed

Trial comparisons

One record for each comparison of two groups in a trial that posted counts to ClinicalTrials.gov: an outcome, serious adverse events or deaths from any cause. ConductScience calculates each group's risk, the risk difference, risk ratio, odds ratio and number needed to treat or harm from the counts in CTTI's AACT copy of 23 Mar 2026, with 95% intervals.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Search Trial comparisons.

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

Try searching

Trial comparisons 85,013

Most participants first33,758 with no events in either group come last1 to 20 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Flublok Recipients vs SD-IIV Recipients: deaths from any cause352 of 632,962

501 of 997,366

0.0 points

-0.0 to 0.0

1,630,328NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Exposed Cohort: Vaccinated With Trumenba + MenACWY vs Non-Exposed Cohort: Vaccinated With MenACWY Only: Number of Participants With Chlamydial Infection After at Least 1 Dose of Trumenba to Determine VE1,138 of 214,552

7,261 of 1,092,826

-0.1 points

-0.2 to -0.1

1,307,378NCT05873751

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

Exposed Cohort: Vaccinated With Trumenba + MenACWY vs Non-Exposed Cohort: Vaccinated With MenACWY Only: Number of Participants With Gonococcal Infection After at Least 1 Dose of Trumenba to Determine Vaccine Effectiveness (VE)316 of 214,552

2,327 of 1,092,826

-0.1 points

-0.1 to -0.0

1,307,378NCT05873751

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

Exposed Cohort: Vaccinated With Trumenba + MenACWY vs Non-Exposed Cohort: Vaccinated With MenACWY Only: Number of Participants With Chlamydial Infection After at Least 2 Doses of Trumenba to Determine VE584 of 92,661

7,261 of 1,092,826

-0.0 points

-0.1 to 0.0

1,185,487NCT05873751

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

Exposed Cohort: Vaccinated With Trumenba + MenACWY vs Non-Exposed Cohort: Vaccinated With MenACWY Only: Number of Participants With Gonococcal Infection After at Least 2 Doses of Trumenba to Determine VE165 of 92,661

2,327 of 1,092,826

-0.0 points

-0.1 to -0.0

1,185,487NCT05873751

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants Who Were New Users of OAC and VKA421,313 of 601,998

0 of 395,461

70.0 points

69.9 to 70.1

997,459NCT05838664

A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France

Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old Hospitalized With Cardio-respiratory Events133 of 353,562

208 of 601,514

0.0 points

-0.0 to 0.0

955,076NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old Hospitalized With Community-acquired Pneumonia37 of 353,562

49 of 601,514

0.0 points

-0.0 to 0.0

955,076NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old Hospitalized With PCR-confirmed Influenza48 of 353,562

88 of 601,514

-0.0 points

-0.0 to 0.0

955,076NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old With All-Cause Mortality66 of 353,562

79 of 601,514

0.0 points

0.0 to 0.0

955,076NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza B Tests146 of 353,562

231 of 601,514

0.0 points

-0.0 to 0.0

955,076NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza Tests827 of 353,562

1,510 of 601,514

-0.0 points

-0.0 to 0.0

955,076NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old With All-Cause-Hospitalizations1,858 of 353,562

2,950 of 601,514

0.0 points

0.0 to 0.1

955,076NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza A Tests682 of 353,562

1,282 of 601,514

-0.0 points

-0.0 to -0.0

955,076NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old With Influenza-Like Illness (ILI)2,904 of 353,562

5,434 of 601,514

-0.1 points

-0.1 to -0.0

955,076NCT03694392

Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants With Atleast One Visit to Nursing Home in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC16,170 of 485,646

31,493 of 332,236

-6.1 points

-6.3 to -6.0

817,882NCT05838664

A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France

Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants Who Were Polymedicated in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC408,403 of 485,646

291,508 of 332,236

-3.6 points

-3.8 to -3.5

817,882NCT05838664

A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France

Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants Who Received Complimentary Universal Health Care (CMU-c) in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC12,819 of 485,646

10,198 of 332,236

-0.4 points

-0.5 to -0.4

817,882NCT05838664

A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France

Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants Who Received Aid for Complementary Health Care (ACS) for Elderly Participants in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC10,444 of 485,646

8,698 of 332,236

-0.5 points

-0.5 to -0.4

817,882NCT05838664

A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France

Participants Exposed to OACs vs Participants Unexposed to OACs: Number of Participants With Contraindications to OAC at Index Date in Non-valvular AF Participants Exposed to OAC and Unexposed to OAC49,478 of 485,646

86,646 of 332,236

-15.9 points

-16.1 to -15.7

817,882NCT05838664

A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03694392-deaths",
        "title": "Flublok Recipients vs SD-IIV Recipients: deaths from any cause",
        "summary": "352 of 632962 against 501 of 997366; risk difference 0.0 points, 95% interval -0.0 to 0.0; NCT03694392, Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years",
        "record": "/library/comparisons/NCT03694392-deaths",
        "nct_id": "NCT03694392",
        "kind": "deaths",
        "participants": 1630328,
        "risk_difference": {
          "value": 0.00005379241390628304,
          "lower": -0.000017967762108580493,
          "upper": 0.0001280617273885157
        },
        "group_1": "352 of 632,962",
        "group_2": "501 of 997,366",
        "difference": "0.0 points",
        "interval": "-0.0 to 0.0",
        "trial_title": "Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years"
      },
      {
        "id": "NCT05873751-16c2f2b2",
        "title": "Exposed Cohort: Vaccinated With Trumenba + MenACWY vs Non-Exposed Cohort: Vaccinated With MenACWY Only: Number of Participants With Chlamydial Infection After at Least 1 Dose of Trumenba to Determine VE",
        "summary": "1138 of 214552 against 7261 of 1092826; risk difference -0.1 points, 95% interval -0.2 to -0.1; NCT05873751, A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.",
        "record": "/library/comparisons/NCT05873751-16c2f2b2",
        "nct_id": "NCT05873751",
        "kind": "outcome",
        "participants": 1307378,
        "risk_difference": {
          "value": -0.0013401661578708538,
          "lower": -0.0016761819324575106,
          "upper": -0.0009898187522996756
        },
        "group_1": "1,138 of 214,552",
        "group_2": "7,261 of 1,092,826",
        "difference": "-0.1 points",
        "interval": "-0.2 to -0.1",
        "trial_title": "A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States."
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=2",
  "request_id": "8Zbu5QRKIFHAE-HS"
}
trial-comparisons-2026-03-23-0.1.0Next page

What it holds

Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?